Novo Nordisk’s Victoza found to cut blood sugar in children
The ELLIPSE trial is the first Phase III trial completed in over a decade in children and adolescents with type II diabetes.
Read More
Tag: liraglutide
EU approves CV benefit claim for Novo’s Victoza
Novo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events.
Read More
Novo gets US backing for Victoza cardiovascular data
US regulatory advisors are backing the claim that Novo Nordisk’s Victoza reduces cardiovascular risk in patients with diabetes.
Read More
Europe expands use of diabetes drug Xultophy
The European Commission has approved the expanded use of Novo Nordisk’s once-daily jab Xultophy in adults with type II diabetes and moderate renal impairment.
Read More
Trial shows heart benefits of Novo’s diabetes drug Victoza
New data on Novo Nordisk’s diabetes therapy Victoza show that the drug significantly cut the risk of major cardiovascular events and death in adults with type II diabetes.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
